Sunday, August 16, 2026 Never miss a recall or a rule change Go Pro · $20/mo →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
InjectablesHugel Posts Record H1 on Toxin Surge—Overseas Growth AcceleratestodayMarketHugel Posts Record H1 Revenue on Overseas Toxin Surge3 days agoDevices & TechApyx: GLP-1 Boom Is Fueling Renuvion DemandtodayMarketMedytox Q2 Sales Up 11%, Operating Profit Down 25%3 days agoInjectablesGalderma Wins EU Nod for Restylane ShaypeyesterdayBusiness & M&AEstablishment Labs Raises 2026 Revenue Guidance2 days agoDevices & TechMerz Ultherapy PRIME Clears FDA for Knee Skin LaxityyesterdayBusiness & M&ABeauty Health Q2 Earnings: Device Demand Steady2 days agoInjectablesHugel Debuts Thechaum Signature with Reduced CrosslinkeryesterdayDevices & TechAlma Launches TitaniumLift™ Multi-Depth RF Protocol2 days agoInjectablesGLP-1 Boom Exposed Filler Limitations—Here's WhyyesterdayInjectablesGalderma Chief: Start GLP-1 Patients on Skin Care First2 days ago
Government Mechanics

Continuing Resolution

A stopgap that keeps the government funded at prior-year levels when Congress misses its appropriations deadline.

Also known as: CR, Stopgap Funding

What it is
A continuing resolution is temporary legislation extending existing funding levels to avoid a lapse in appropriations. It typically freezes spending at the prior year's rate and blocks new-start programs. CRs can last days or months.
What it does
A CR removes shutdown risk short term but freezes new program starts, delaying fresh contract awards and ramp-ups. That is a headwind for contractors counting on growth line items. Markets often relieve on a CR passing but discount delayed new business.
The evidence
Government-services and defense stocks tend to catch a relief bid when a CR averts a shutdown, even as new-start delays cap upside.
Best for
Gov-services and defense names like LDOS, SAIC, BAH, GD.
Pairs well with
appropriations, government-shutdown, debt-ceiling
Use cautiously with
A CR is not a win for growth; it caps new starts, so treating it as bullish for ramping programs misreads the mechanics.
Cautions
CRs often stack, so the resolution can itself become a recurring source of uncertainty.
General information, not medical advice. Ingredient effects vary by formulation, concentration, and skin. Patch-test new actives and consult a qualified provider before starting prescription ingredients.

Know what's coming before your patients ask for it.

New actives, device launches, and the FDA calls that change what you can offer — distilled into a two-minute brief, twice a week. Inside MedSpa Pro.

Go Pro · $20/mo
Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.
The twice-a-week intelligence brief Go Pro · $20/mo